Semaglutide uses

Semaglutide for Obesity, Diabetes, NASH and Neurogenerative Diseases

April 22, 2024 By , , , , ,

Semaglutide, a GLP-1 receptor agonist, has been clinically approved for treating type 2 diabetes and obesity. Diabetes, insulin resistance, and obesity are responsible for the pathological manifestations of non-alcoholic steatohepatitis (NASH). Similarly, insulin resistance in the brain is also responsible for neurodegeneration and impaired cognitive functions.  We are finding a great deal of research being done to look at the mechanism that Semaglutide can slow the neurodegenerative processes of Alzheimer’s disease and Parkinson’s Disease. At The Natural Path, we have created an excellent medically supervised weight loss protocol using Semaglutide and look forward to its other uses in the future.

Semaglutide usesTrials Using Semaglutide to Treat NASH and Neurodegenerative Diseases

Observations from phase-3 clinical trials like SUSTAIN and PIONEER clearly showed the anti-obesity potential of semaglutide, which was further established in the STEP trials. Various pre-clinical and phase-2 studies have also indicated the therapeutic potential of semaglutide in non-alcoholic steatohepatitis (NASH) and neurodegenerative disorders like Parkinson’s and Alzheimer’s disease. We are excited to learn more about the potential of Semaglutide to help other disease processes.

Discussion of the Semagutide Clinical Trials

Significant weight loss was demonstrated with the use of semaglutide in various phase-3 clinical trials.  Recently, Semaglutide became the first long-acting GLP-1 receptor agonist to be approved by the United States Food and Drug Administration for the management of obesity. Various pre-clinical and clinical studies have revealed the hepatoprotective effect of Semaglutide in NASH and the neuroprotective effect in Parkinson’s and Alzheimer’s disease.  This is really exciting news.

Conclusion of the Semaglutide Clinical Trials

In animal and human trials, many GLP-1 receptor agonists have shown hepatoprotective and neuroprotective activity. As Semaglutide is an already clinically approved drug, successful human trials would advance it in the treatment of NASH and neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Semaglutide improves insulin resistance and insulin signaling pathways and reduces body weight, which is responsible for the prevention or progression of NASH and neurodegenerative diseases.

Tags: , , , , , , , , ,

Categories: , , , , ,